ACVR2B: IHC Expression in Cancer and Radioligand Target Profile
ACVR2B, activin A receptor type 2B, is a cell-surface protein (membrane receptor). In Human Protein Atlas immunohistochemistry, ACVR2B staining is highest in kidney cancer (82% of samples positive), breast cancer (55% of samples positive) and pancreatic cancer (80% of samples positive). Evidence on whether ACVR2B internalizes is mixed. Clinical status: FDA-approved drug (any modality).
Is ACVR2B the right target for your program? Rank it against 15,000 targets on dosimetry, internalization and clinical risk.
Analyze ACVR2B freeIs ACVR2B a good radioligand therapy target?
Scored against the six criteria that decide whether a protein can become a radioligand therapy:
- ✅ Cell-surface accessibility: Localized to the cell surface, so a radioligand can reach it from circulation.
- ⚠️ Tumor expression: Medium IHC staining in kidney cancer, 82% of samples positive.
- ⚠️ Internalization: Mixed evidence.
- ✅ Clinical precedent: FDA-approved drug (any modality)
- ❔ Shedding: Not yet assessed.
- ❔ Normal-tissue dosimetry: Check kidney, liver, bone marrow and salivary expression in the Human Protein Atlas tissue atlas.
ACVR2B IHC staining by cancer type
Protein expression of ACVR2B across 20 cancer types from Human Protein Atlas immunohistochemistry. The score is a weighted staining intensity from 0 to 1; "% positive" is the share of patient samples with detectable staining.
| Cancer type | IHC score | Level | % positive |
|---|---|---|---|
| Kidney Cancer | 0.36 | Medium | 82% |
| Breast Cancer | 0.30 | Medium | 55% |
| Pancreatic Cancer | 0.30 | Medium | 80% |
| Testicular Cancer | 0.28 | Medium | 42% |
| Head and Neck Cancer | 0.25 | Medium | 50% |
| Thyroid Cancer | 0.25 | Medium | 50% |
| Lymphoma | 0.25 | Medium | 42% |
| Glioma | 0.17 | Low | 40% |
| Cervical Cancer | 0.14 | Low | 33% |
| Skin Cancer | 0.14 | Low | 25% |
| Melanoma | 0.14 | Low | 25% |
| Colorectal Cancer | 0.13 | Low | 30% |
| Liver Cancer | 0.11 | Low | 33% |
| Bladder Cancer | 0.11 | Low | 25% |
| Ovarian Cancer | 0.09 | Low | 18% |
| Neuroendocrine Tumors | 0.08 | Low | 25% |
| Lung Cancer | 0.07 | Low | 10% |
| Endometrial Cancer | 0.06 | Low | 18% |
| Gastric Cancer | 0.06 | Low | 8% |
| Prostate Cancer | 0.03 | Low | 9% |
Is ACVR2B internalized?
Uncertain. Insufficient literature found.
ACVR2B clinical trials
FDA-approved drug (any modality). Nuclens hasn't indexed trials for ACVR2B yet. Search ClinicalTrials.gov for ACVR2B trials.
ACVR2B normal tissue expression
Normal-tissue expression in dose-limiting organs (kidney, liver, bone marrow, salivary glands) drives radioligand dosimetry risk. Nuclens is re-validating its normal-tissue values, so they are not shown here yet. See ACVR2B in the Human Protein Atlas tissue atlas, and read how normal-tissue expression predicts radioligand dosimetry risk.
ACVR2B gene essentiality (DepMap)
CRISPR knockout effect across 1258 cancer cell lines: 0.06 (not essential). Radioligands kill by radiation, not by blocking the target, so essentiality matters less than for inhibitors. A non-essential target can still be an excellent radioligand target.
Related kidney cancer radioligand targets
EGFR · c-MET (MET) · HER3 (ERBB3) · ITGAV · STEAP2 · Mesothelin (MSLN) · SSTR2 · HER2 (ERBB2)
See all radioligand therapy targets in kidney cancer.
See how ACVR2B ranks against 15,000 targets for your indication.
Analyze ACVR2B freeData sources
Subcellular localization: UniProt via Open Targets (CC BY 4.0 / CC0). Tumor immunohistochemistry: Human Protein Atlas (CC BY-SA 4.0). Clinical trials: ClinicalTrials.gov (public domain). Gene essentiality: DepMap (CC BY 4.0). Internalization and shedding: AI-extracted from PubMed abstracts, so verify against the cited papers before relying on them. Nuclens is a first-pass triage layer, not a substitute for wet-lab validation or clinical dosimetry. Derived expression data on this page is shared under CC BY-SA 4.0.